We evaluated the efficacy and safety of the nontaxane microtubule dynamics inhibitor eribulin plus the humanized anti-VEGF monoclonal antibody bevacizumab in a novel second-line chemotherapy scheme in HER2-negative metastatic breast cancer (MBC) patients progressing after first-line paclitaxel and bevacizumab.
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) / De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., Gamucci, T., De Placido, P., Poggio, F., Russo, S., Forestieri, V., Lauria, R., De Santo, I., Michelotti, A., Del Mastro, L., De Laurentiis, M., Giuliano, M., De Placido, S., Arpino, G.. - In: ESMO OPEN. - ISSN 2059-7029. - 6:2(2021), p. 100054. [10.1016/j.esmoop.2021.100054]
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
De Angelis, CPrimo
;Bruzzese, D;Bernardo, A;Baldini, E;De Placido, P;Forestieri, V;Lauria, R;De Santo, I;Michelotti, A;De Laurentiis, M;Giuliano, M;De Placido, SPenultimo
;Arpino, GUltimo
2021
Abstract
We evaluated the efficacy and safety of the nontaxane microtubule dynamics inhibitor eribulin plus the humanized anti-VEGF monoclonal antibody bevacizumab in a novel second-line chemotherapy scheme in HER2-negative metastatic breast cancer (MBC) patients progressing after first-line paclitaxel and bevacizumab.| File | Dimensione | Formato | |
|---|---|---|---|
|
main.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
329.15 kB
Formato
Adobe PDF
|
329.15 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
